Updates are available Correction dated 2025-06-09
Click to view Correction: https://doi.org/10.1007/s12282-025-01729-z
-
Authors
Akita, Yumiko https://orcid.org/0009-0001-7333-5448
Velaga, Ravi
Iwase, Madoka
Shimada, Satoko
Kikumori, Toyone
Takeuchi, Dai
Takano, Yuko
Ichikawa, Takahiro
Ebata, Tomoki
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
-
Funding
Funding for this research was provided by:
Moonshot Research and Development Program (JP22zf0127009)
Nagoya University
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 30 April 2025
First Online: 18 May 2025
Change Date: 1 June 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct the article title.
Change Date: 9 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-025-01729-z
Declarations
:
: Norikazu Masuda has received honoraria (e.g., lecture fees) from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Pfizer. He has also received research funding from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, MSD, Novartis, Ono Pharmaceutical, and Pfizer. Additionally, he holds positions on the Board of Directors for the Japanese Breast Cancer Society (JBCS; 2021–2024), the Japan Society of Clinical Oncology (JSCO; 2023–present), and the Japan Breast Cancer Research Group Association (JBCRG; 2021–present).
